PARVOVIRUS PARTICLES AS PLATFORMS FOR PROTEIN PRESENTATION

被引:38
作者
MIYAMURA, K
KAJIGAYA, S
MOMOEDA, M
SMITHGILL, SJ
YOUNG, NS
机构
[1] NHLBI,HEMATOL BRANCH,BETHESDA,MD 20892
[2] NCI,GENET LAB,BETHESDA,MD 20892
关键词
CAPSID; B19; LYSOZYME; GENE THERAPY; VACCINE;
D O I
10.1073/pnas.91.18.8507
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Empty capsids of the human pathogenic parvovirus B19 can be produced in a baculovirus system. B19 capsids are composed mainly of major capsid protein (VP2) and a small amount of minor capsid protein (VP1); VP1 is identical to VP2 but contains an additional 227-aa N-terminal region (''unique'' region). A portion of that region of VP1 is external to the capsid, and VP1 is not required for capsid formation. We substituted the unique region with a sequence encoding the 147 aa of hen egg white lysozyme (HEL) and constructed recombinant baculoviruses with variable amounts of retained VP1 sequence joined to the VP2 backbone. After cotransfection with VP2 baculovirus and expression in insect cells, capsids were purified by density sedimentation. Purified recombinant capsids contained HEL, External presentation of HEL was demonstrated by immunoprecipitation, ELISA, and immune electron microscopy using anti-lysozyme monoclonal antibodies or specific rabbit antisera. Empty particles showed enzymatic activity in a micrococcal cell wall digestion assay. Rabbits inoculated with capsids made antibodies to HEL. Intact heterologous protein can be incorporated in B19 particles and presented on the capsid surface, properties that may be useful in vaccine development, cell targeting, and gene therapy.
引用
收藏
页码:8507 / 8511
页数:5
相关论文
共 37 条
[1]   PRELIMINARY-X-RAY CRYSTALLOGRAPHIC INVESTIGATION OF HUMAN PARVOVIRUS-B19 [J].
AGBANDJE, M ;
MCKENNA, R ;
ROSSMANN, MG ;
KAJIGAYA, S ;
YOUNG, NS .
VIROLOGY, 1991, 184 (01) :170-174
[2]  
AGBANDJE M, 1994, IN PRESS VIROLOGY
[3]   CONSTRUCTION AND CHARACTERIZATION OF A POLIOVIRUS RHINOVIRUS ANTIGENIC HYBRID [J].
ALTMEYER, R ;
MURDIN, AD ;
HARBER, JJ ;
WIMMER, E .
VIROLOGY, 1991, 184 (02) :636-644
[4]   CANDIDATE RECOMBINANT VACCINE FOR HUMAN B19-PARVOVIRUS [J].
BANSAL, GP ;
HATFIELD, JA ;
DUNN, FE ;
KRAMER, AA ;
BRADY, F ;
RIGGIN, CH ;
COLLETT, MS ;
YOSHIMOTO, K ;
KAJIGAYA, S ;
YOUNG, NS .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (05) :1034-1044
[5]  
BEESLEY JE, 1989, COLLOIDAL GOLD PRINC, P244
[6]  
BERNS KI, 1990, VIROLOGY, P1743
[7]   CHIMERIC PARVOVIRUS B19 CAPSIDS FOR THE PRESENTATION OF FOREIGN EPITOPES [J].
BROWN, CS ;
WELLINGWESTER, S ;
FEIJLBRIEF, M ;
VANLENT, JWM ;
SPAAN, WJM .
VIROLOGY, 1994, 198 (02) :477-488
[8]   ERYTHROCYTE-P ANTIGEN - CELLULAR RECEPTOR FOR B19 PARVOVIRUS [J].
BROWN, KE ;
ANDERSON, SM ;
YOUNG, NS .
SCIENCE, 1993, 262 (5130) :114-117
[9]   ANTIGEN CHIMERAS OF POLIOVIRUS AS POTENTIAL NEW VACCINES [J].
BURKE, KL ;
DUNN, G ;
FERGUSON, M ;
MINOR, PD ;
ALMOND, JW .
NATURE, 1988, 332 (6159) :81-82
[10]  
CARTER BJ, 1990, HDB PARVOVIRUSES, V2, P247